注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Sarepta Therapeutics Inc是一家商业阶段的生物制药公司。该公司专注于帮助患者发现和开发核糖核酸(RNA)靶向疗法、基因疗法和其他用于治疗罕见疾病的基因疗法。其正在开发治疗各种疾病和障碍的候选药物,包括杜氏肌营养不良症(Duchenne)、肢带型肌营养不良症(LGMDs)和其他神经肌肉和中枢神经系统(CNS)相关疾病。其商业产品EXONDYS 51(eteplirsen)注射剂、VYONDYS 53(golodirsen)注射剂和AMONDYS 45(casimersen)注射剂用于治疗DMD患者,这些患者有确认的DMD基因突变,可以跳过51外显子、53外显子和45外显子。该公司还包括40多个处于发现、临床前和临床开发不同阶段的项目。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Douglas S. Ingram | 58 | 2017 | President, CEO & Director |
M. Kathleen Behrens | 69 | 2009 | Independent Chairwoman |
Beverly L. Davidson | - | 2015 | Member of Strategic & Scientific Advisory Board |
Hans Wigzell | 83 | 2010 | Chairman of Corporate Strategy Board & Independent Non-Employee Director |
Louis M. Kunkel | - | 2015 | Member of Strategic & Scientific Advisory Board |
Kenneth H. Fischbeck | - | 2017 | Member of Strategic & Scientific Advisory Board |
Matthew Wood | - | 2017 | Member of Strategic & Scientific Advisory Board |
Steven Gray | - | 2019 | Member of Scientific Advisory Board |
Angela J. Russell | - | 2020 | Member of Scientific Advisory Board |
Carsten Bonnemann | - | 2019 | Member of Scientific Advisory Board |
Kay Davies | - | 2019 | Member of Scientific Advisory Board |
Annemieke Aartsma-Rus | - | 2019 | Member of Scientific Advisory Board |
Joy A. Cavagnaro | - | 2019 | Member of Scientific Advisory Board |
Stephen L. Mayo | 60 | 2021 | Independent Director |
Michael Chambers | 48 | 2022 | Independent Director |
Kathryn J. Boor | 64 | 2022 | Independent Director |
Claude Nicaise | 70 | 2015 | Independent Non-Employee Director |
Richard Jon Barry | 64 | 2015 | Independent Director |
Deirdre P. Connelly | 63 | 2024 | Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核